Proactive Investors
07 Oct 2026, 07:19 UTC · 2h ago
Futura Medical plans 2027 Eroxon Intense launch after positive test
Impact · against what's priced in
Futura Medical's improved efficacy data for Eroxon Intense provides a positive outlook for its 2027 launch, though the long timeline limits immediate impact. Incanthera's shift to a recurring revenue model via a B2B deal marks a strategic pivot that improves its business stability.
- FUM+0.60
No priced-in read yet
- In context
The increase in IIEF-EF score to 7.86 and the 87% success rate for moderate ED cases suggest the Intense version will have higher efficacy and a larger addressable market than the standard product.
Read from the article alone
Search tags
